Back

Pericyte-Derived Cancer-Associated Fibroblasts Correlate with Poor Survival and Are Enriched After Chemoradiotherapy in Glioblastoma

Ismailov, A.; Poptsova, M.

2026-07-09 cancer biology
10.64898/2026.07.02.736148 bioRxiv
Show abstract

The role of cancer-associated fibroblasts (CAFs) in glioblastoma remains unclear, as their existence in the brain tumor microenvironment is still debated, given that the normal brain parenchyma is devoid of fibroblasts. It is unclear whether cells described as CAFs represent a distinct stromal population or a transcriptional state of perivascular cells such as pericytes. The aim of this study was to determine the identity, origin, and functional relevance of CAFs in glioblastoma. We analyzed 54 single-cell RNA sequencing datasets together with 88 bulk RNA sequencing samples. We identified a continuous transcriptional spectrum linking endothelial cells, pericytes, and CAFs, supporting pericytes as the most likely source of CAFs in glioblastoma. We further derived and validated robust CAF- and pericyte-specific gene signatures, enabling clear separation of these populations across cohorts. Reproducible CAF-associated ligand-receptor interactions were enriched in angiogenesis and immune modulation pathways. In bulk RNA-seq data, both CAF signature scoring and deconvolution consistently demonstrated increased CAF abundance in IDH-wildtype gliomas and further enrichment after chemoradiotherapy, while selective CYP1B1 expression in CAFs suggested a potential association with therapy-induced tumor adaptation. Overall, CAFs represent a distinct, pericyte-related stromal population in glioblastoma with conserved transcriptional and signaling programs. High CAF signature scores were associated with poorer overall and progression-free survival and were enriched in IDH-wildtype and post-chemoradiotherapy gliomas, suggesting a role for CAFs in therapy-associated remodeling of the tumor microenvironment in aggressive disease.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Nature Communications
5641 papers in training set
Top 14%
12.6%
2
Neuro-Oncology
36 papers in training set
Top 0.1%
10.6%
3
Neuro-Oncology Advances
25 papers in training set
Top 0.1%
10.6%
4
Cell Reports
1498 papers in training set
Top 5%
6.7%
5
Acta Neuropathologica Communications
89 papers in training set
Top 0.4%
5.5%
6
Journal of Neuro-Oncology
10 papers in training set
Top 0.1%
4.0%
7
Cancer Research
130 papers in training set
Top 1%
3.4%
50% of probability mass above
8
Genome Medicine
183 papers in training set
Top 1%
3.2%
9
Journal of Neuroinflammation
61 papers in training set
Top 0.5%
3.1%
10
Cancer Cell
42 papers in training set
Top 0.6%
2.1%
11
JCI Insight
277 papers in training set
Top 3%
2.1%
12
Acta Neuropathologica
58 papers in training set
Top 0.7%
2.0%
13
Scientific Reports
3612 papers in training set
Top 51%
1.9%
14
Molecular Cancer
16 papers in training set
Top 0.1%
1.7%
15
Cell Reports Medicine
153 papers in training set
Top 2%
1.7%
16
Clinical Cancer Research
64 papers in training set
Top 1%
1.7%
17
Cell Communication and Signaling
51 papers in training set
Top 0.6%
1.7%
18
Glia
81 papers in training set
Top 1.0%
1.3%
19
Communications Medicine
113 papers in training set
Top 4%
1.0%
20
Molecular Oncology
55 papers in training set
Top 1%
1.0%
21
PLOS ONE
5266 papers in training set
Top 60%
0.9%
22
EMBO Molecular Medicine
95 papers in training set
Top 2%
0.9%
23
Nature Cancer
39 papers in training set
Top 1%
0.8%
24
Cell Death & Disease
21 papers in training set
Top 0.4%
0.8%
25
Communications Biology
993 papers in training set
Top 31%
0.8%
26
Neoplasia
23 papers in training set
Top 1%
0.6%
27
Cancer Discovery
66 papers in training set
Top 2%
0.6%
28
Science Translational Medicine
127 papers in training set
Top 4%
0.6%
29
Science Advances
1243 papers in training set
Top 33%
0.6%
30
npj Precision Oncology
53 papers in training set
Top 2%
0.6%